April 10, 2026 — Celltrion, South Korea's leading biopharmaceutical company, has unveiled a massive KRW 1.2+ trillion ($850M+) capacity expansion plan that will nearly double its drug substance (DS) manufacturing capability — from 316,000 to 571,000 liters — by 2031. The investment, which includes a significant expansion of its U.S. facility in Branchburg, New Jersey, sends a powerful signal to API intermediates suppliers, single-use technology providers, and bioprocessing equipment manufacturers: the biologics CDMO boom is accelerating.
The announcement, made on April 8, comes as Celltrion's cumulative contract manufacturing organization (CMO) order backlog surpassed KRW 1 trillion ($700M) within the first quarter of 2026, driven by consecutive contract wins including a landmark KRW 678.7 billion deal with Eli Lilly and a follow-on agreement valued at up to KRW 375.4 billion with an undisclosed global pharmaceutical company.
The expansion plan encompasses multiple sites across Korea and the United States, reflecting Celltrion's dual-track manufacturing strategy designed to serve both domestic efficiency and U.S. market access:
Songdo, Korea (Headquarters): Celltrion will invest KRW 1.2265 trillion to construct Plants 4 and 5 with a combined capacity of 180,000 liters at its Songdo campus in Incheon. The new facilities will incorporate advanced automation and smart factory technologies, enabling flexible production from small-batch, multi-product runs to large-scale commercial manufacturing. A new drug product (DP) plant under construction at the same campus — over 70% complete — will add 6.5 million liquid vials per year, bringing total DP capacity at Songdo to approximately 10.5 million vials annually.
Branchburg, New Jersey (U.S.): The planned U.S. expansion has been increased from the originally proposed 66,000 liters to 75,000 liters, doubling the facility's capacity from 66,000 to 141,000 liters. The Branchburg site is positioned to serve as a local supply hub for Celltrion's own products and third-party CMO production, directly addressing growing demand for domestic biologics manufacturing in the United States.
Yesan, Korea: A new DP manufacturing facility has been finalized at Yesan Industrial Complex in Chungcheongnam-do, with design work scheduled to begin within 2026. Combined with planned pre-filled syringe (PFS) manufacturing expansion by subsidiary Celltrion Pharm, the company targets 90% internalization of global DP supply.
Several converging forces are fueling Celltrion's aggressive expansion and the broader biologics CDMO demand surge:
Biosimilar Pipeline Expansion: Celltrion has set a target of 41 biosimilar products by 2038, up from its current portfolio of approved and marketed products. Each new biosimilar requires dedicated manufacturing capacity for both drug substance and drug product, creating predictable, long-term capacity demand. The company's recent commercial successes — including Zymfentra (Remsima SC in the U.S.) — are generating revenue that funds both pipeline development and manufacturing investment.
Global CMO/CDMO Demand: The pharmaceutical industry's shift toward outsourcing biologics manufacturing continues to accelerate. Celltrion's CMO order backlog growing from zero to KRW 1 trillion within a single quarter reflects the intensity of demand from global pharma companies seeking reliable, high-quality manufacturing partners. The company's "formulation conversion CMO" offering — leveraging proprietary subcutaneous formulation technology developed through Remsima SC and Herzuma SC — adds a differentiated, higher-margin service layer beyond traditional contract manufacturing.
Supply Chain Regionalization: Geopolitical tensions and trade policy uncertainty — including periodic threats of pharmaceutical tariffs — are driving demand for geographically diversified manufacturing. Celltrion's expansion of its Branchburg facility directly responds to this trend, enabling U.S.-based production that avoids potential tariff exposure and reduces supply chain risk for American customers.
Celltrion's expansion creates significant opportunities across the bioprocessing supply chain:
Single-use bioreactor systems: Modern biologics facilities increasingly rely on single-use technology for flexibility and reduced cross-contamination risk. Celltrion's smart factory approach suggests high adoption of disposable bioreactor bags, tubing assemblies, and filtration systems from suppliers such as Sartorius, Cytiva, and Merck
Cell culture media and feeds: Scaling from 316,000 to 571,000 liters of DS capacity implies proportional increases in demand for high-quality cell culture media, growth factors, and feed supplements
Chromatography resins: Protein A affinity chromatography remains the gold standard for monoclonal antibody purification. Expanded capacity translates directly to increased resin consumption and replacement cycles
Analytical and quality control instrumentation: Each new facility requires comprehensive analytical capability — HPLC, mass spectrometry, bioassay platforms — creating demand for instrumentation vendors
Automation and digital manufacturing: Celltrion's emphasis on smart factory technology and advanced automation points to growing adoption of process analytical technology (PAT), real-time release testing, and digital twin capabilities
Clean utility systems: Large-scale biologics manufacturing requires significant water-for-injection (WFI), clean steam, and HVAC infrastructure, benefiting equipment suppliers in these categories
Celltrion's decision to double its Branchburg capacity is particularly significant in the current trade policy environment. With the U.S. government periodically signaling pharmaceutical import tariffs and actively promoting domestic manufacturing through incentives and regulatory preferences, having a U.S.-based production footprint is becoming a competitive differentiator for global biopharma companies.
The Branchburg expansion positions Celltrion to serve as both a self-manufacturing hub and a CMO partner for other companies seeking U.S.-based biologics production without building their own facilities — a trend that benefits the entire domestic bioprocessing ecosystem.
Celltrion's expansion is part of a broader wave of biologics manufacturing investment across Asia. Samsung Biologics, its primary Korean competitor, operates the world's largest biologics contract manufacturing facility with over 600,000 liters of capacity at its Incheon site. WuXi Biologics in China has similarly expanded aggressively, with multiple sites across China, Ireland, Germany, and Singapore.
The competitive dynamic is creating a virtuous cycle for suppliers: as leading CDMOs invest in capacity, they drive demand for upstream materials and equipment, which in turn attracts further investment in supplier infrastructure and innovation.
Celltrion's KRW 1.2+ trillion investment program — targeting completion by 2031 — provides exceptional visibility into biologics manufacturing demand for the next five years. For API intermediates suppliers, bioprocessing equipment manufacturers, and analytical service providers, the message is clear: the biologics CDMO capacity expansion cycle is in its early innings, and suppliers positioned with validated, scalable offerings will capture growing share of this multi-billion-dollar opportunity.
With 100% DS internalization and 90% DP internalization as stated goals, Celltrion is also signaling that vertically integrated biopharma companies — even those with significant CMO businesses — will continue to invest in proprietary capacity alongside contract manufacturing, ensuring demand across both channels.
